Arcus Biosciences (NYSE:RCUS) vs. Sarepta Therapeutics (NASDAQ:SRPT) Financial Survey

Arcus Biosciences (NYSE:RCUS – Get Free Report) and Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Risk & Volatility

Arcus Biosciences has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500.

Valuation and Earnings

This table compares Arcus Biosciences and Sarepta Therapeutics”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Arcus Biosciences $247.00 million 10.17 -$353.00 million ($3.63) -4.81
Sarepta Therapeutics $2.20 billion 0.78 -$713.41 million ($1.37) -11.73

Arcus Biosciences has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are held by institutional investors. 7.6% of Arcus Biosciences shares are held by company insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Arcus Biosciences and Sarepta Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Arcus Biosciences -453.00% -91.65% -46.72%
Sarepta Therapeutics -5.86% -0.20% -0.09%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Arcus Biosciences and Sarepta Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcus Biosciences 1 3 12 0 2.69
Sarepta Therapeutics 6 6 6 0 2.00

Arcus Biosciences currently has a consensus price target of $39.36, indicating a potential upside of 125.58%. Sarepta Therapeutics has a consensus price target of $23.67, indicating a potential upside of 47.27%. Given Arcus Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Arcus Biosciences is more favorable than Sarepta Therapeutics.

Summary

Arcus Biosciences beats Sarepta Therapeutics on 9 of the 14 factors compared between the two stocks.

About Arcus Biosciences

(Get Free Report)

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Founded in 2015 and headquartered in Hayward, California, the company researches therapies that target immune pathways and other processes involved in tumor growth. Its pipeline consists of investigational medicines, including antibody and small-molecule candidates designed to be used alone or in combination. Arcus’s research has focused on areas such as checkpoint inhibition and the adenosine pathway; its candidates are under clinical development and are not established treatments.

About Sarepta Therapeutics

(Get Free Report)

Sarepta Therapeutics is a biotechnology company focused on developing genetic medicines for rare diseases, with an emphasis on Duchenne muscular dystrophy (DMD). Its research includes RNA-based treatments designed to affect how genetic instructions are processed, as well as gene therapy approaches. The company’s DMD medicines include exon-skipping therapies such as eteplirsen (Exondys 51), golodirsen (Vyondys 53) and casimersen (Amondys 45). Each is intended for patients with a specific genetic mutation and works by helping cells produce a shortened form of dystrophin, a protein affected by DMD.

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.